Pinealon

Mechanism

Pinealon is a short three-amino-acid peptide designed to support the pineal gland, the part of your brain that produces melatonin and regulates your sleep-wake cycle. It helps normalize melatonin production naturally, which can improve sleep quality, support circadian rhythm balance, and provide antioxidant protection to brain cells. It is part of a class of Russian bioregulator peptides developed to restore organ function at the genetic level.

Effects

## Pinealon — System-by-System Effects ### Central Nervous System (Primary Target) - **Pineal gland function**: Pinealon is a tripeptide (Glu-Asp-Arg) bioregulator targeting pineal gland tissue. Designed to restore optimal melatonin synthesis and pineal gland gene expression in aging. [Tier 2 — Khavinson bioregulator research] - **Melatonin production**: Stimulates pinealocyte melatonin synthesis capacity. Aging pineal glands calcify and reduce melatonin output; pinealon may counteract this decline. [Tier 2] - **Neuroprotection**: Demonstrated neuroprotective effects in cell culture models of oxidative stress. Reduces neuronal apoptosis and improves cell survival under stress conditions. [Tier 2 — published in vitro studies] - **Cognitive function**: Patients report improved mental clarity, focus, and memory, particularly in elderly populations. Likely mediated through improved sleep quality and circadian function. [Tier 3 — clinical observation] ### Sleep & Circadian System - **Circadian rhythm regulation**: By supporting endogenous melatonin production, pinealon may help normalize disrupted circadian rhythms — particularly relevant for aging, shift workers, and jet lag. [Tier 2-3] - **Sleep architecture**: Improved melatonin production should enhance slow-wave sleep and overall sleep quality. Patients often report deeper, more restorative sleep within 2-3 weeks. [Tier 3] - **Sleep onset**: May reduce sleep latency through restored evening melatonin surge. [Tier 3] ### Immune/Antioxidant System - **Melatonin as immunomodulator**: Melatonin is a potent antioxidant and immune modulator. By restoring melatonin levels, pinealon indirectly supports immune surveillance and reduces oxidative stress. [Tier 1 for melatonin biology, Tier 2 for pinealon-mediated benefit] - **Anti-inflammatory**: Melatonin suppresses NF-κB and reduces inflammatory cytokine production. Improved melatonin levels from pinealon use may contribute to reduced systemic inflammation. [Tier 2] ### Reproductive/Hormonal System - **Circadian hormone cascade**: Melatonin is upstream of many hormonal rhythms. Restoring proper melatonin cycling may improve cortisol rhythm, growth hormone pulsatility, and sex hormone regulation. [Tier 2 — endocrine physiology] - **Pineal-hypothalamic communication**: The pineal gland communicates with the hypothalamus to regulate reproductive cycling and seasonal adaptations. [Tier 2] ### Aging/Longevity - **Anti-aging bioregulator**: Khavinson's research positions pinealon as one of the key anti-aging bioregulators. The pineal gland is considered a master clock of aging in this framework — its decline accelerates systemic aging. [Tier 2 — Khavinson bioregulation theory] - **Epitalon comparison**: Pinealon is the oral bioregulator complement to epitalon (injectable). Both target the pineal gland but through different mechanisms. [Tier 2]

Practitioner Guide

## Pinealon — Practitioner Guide ### Clinical Profile Pinealon is a synthetic tripeptide (Glu-Asp-Arg) bioregulator targeting the pineal gland. It belongs to the Khavinson cytogens class — synthetically produced short peptides that mimic the effects of tissue-extracted cytomaxes. ### Typical Protocols - **Standard course**: 1-2 capsules daily for 30 days, repeat 2-3 times per year - **Sleep-focused**: 1-2 capsules in the evening, 1-2 hours before bed - **Loading**: 2 capsules twice daily for first 10 days, then 1 capsule daily - **Combined with epitalon**: Use pinealon during the intervals between epitalon injection courses ### Best Candidates - Aging patients (50+) with declining sleep quality - Patients with disrupted circadian rhythms (shift workers, frequent travelers) - Those with pineal gland calcification on imaging - Patients who want to reduce dependence on exogenous melatonin supplements - Elderly patients with cognitive decline and poor sleep (the two are connected) ### Combination Strategies - **Sleep optimization**: Pinealon + magnesium glycinate + glycine + reduced evening blue light - **Bioregulator anti-aging**: Pinealon (pineal) + Cerluten (brain) + Ventfort (vessels) — comprehensive aging protocol - **Pineal restoration**: Pinealon (oral, ongoing) + Epitalon (injectable, periodic courses) — dual pineal support - **Circadian + hormonal**: Pinealon + morning light exposure + timed eating — circadian alignment stack ### Clinical Observations - Most patients notice sleep improvements within 10-14 days - Benefits appear to accumulate with repeated courses - Well tolerated; no significant adverse effects reported - Some patients can reduce or eliminate exogenous melatonin use after 2-3 courses - Best results when combined with circadian hygiene practices (light exposure, meal timing) - Elderly patients with severe pineal calcification may respond more slowly ### Important Distinctions - Pinealon is NOT exogenous melatonin — it supports the gland's own production capacity - This approach is more physiological than taking melatonin supplements, which can suppress endogenous production - Pinealon is the oral complement to injectable epitalon; they are not interchangeable but are complementary

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No human safety data during pregnancy. Bioregulator peptide that modulates gene expression in the pineal gland and CNS poses theoretical risk to fetal neurodevelopment and circadian system formation.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. CNS-active bioregulator peptide exposure in nursing infant poses unknown risk.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Effects on developing pineal gland and circadian rhythm maturation unknown.
  Action: Do not provide peptide protocols to individuals under 18.
• caution — General use
  Limited human safety data. Pinealon is a Russian bioregulator peptide without Phase III clinical trial data or regulatory approval outside Russia. Long-term safety profile not established.
  Action: Use with awareness of limited evidence base. Monitor for unexpected effects. Report any adverse reactions.

Evidence

• INFLUENCE OF PINEALON ON EXPRESSION OF GENES OF PRO- AND ANTIOXIDANT ENZYMES AND FREE RADICAL PROCESSES IN RATS IN THE MODEL OF SUGAR DIABETES

  M.P. Fomenko, A.M. Menzheritsky, G.V. Karantysh (2020) — State and Development Prospects of Agribusiness / Interagromash Forum Proceedings

  In a streptozotocin-diabetes rat model, pinealon shifted the pro/antioxidant balance toward lower free-radical production and higher antioxidant defense in hippocampal tissue, with the 100 ng/kg dose outperforming 50 ng/kg.

  emerging

• EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

  Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. (2020) — Molecules — PMID: 33396470

  Review summarizes preclinical and limited human-aging observations suggesting the EDR tripeptide modulates MAPK/ERK signaling, antioxidant-enzyme expression, apoptotic proteins, and transcriptional programs relevant to neurodegeneration. The paper presents mechanistic plausibility rather than definitive clinical efficacy in Alzheimer disease.

  strong

• [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]

  A M Mendzheritskii et al. (2014) — Adv Gerontol. — PMID: 25051764

  In aged rats exposed to acute hypoxic hypoxia, pinealon lowered neuroinflammatory markers toward reference levels and was associated with reduced caspase-3 activity, suggesting less apoptotic signaling under hypoxic stress.

  strong

• Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.

  Arutjunyan A et al. (2012) — Int J Clin Exp Med. — PMID: 22567179

  In a rat prenatal hyperhomocysteinemia model, maternal pinealon improved offspring spatial learning and reduced oxidative-stress and neuronal-necrosis markers in cerebellar cells, supporting neuroprotective effects.

  emerging

• Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.

  Khavinson V et al. (2011) — Rejuvenation Res. — PMID: 21978084

  In cerebellar granule cells, neutrophils, and PC12 cells, pinealon dose-dependently reduced ROS accumulation, lowered necrotic cell death, and altered ERK/cell-cycle signaling consistent with cytoprotective activity.

  emerging

Stacks featuring this peptide

Research Summary

## Pinealon — Research Summary ### Tier 1 (Strong Clinical Evidence) - No Western RCTs for pinealon specifically. Melatonin biology and its role in health/aging is well established (Tier 1). ### Tier 2 (Moderate Evidence) - Published in vitro studies showing pinealon (EDR peptide) reduces oxidative stress and apoptosis in neuronal cell cultures (Khavinson et al., various publications). - Bioregulator research program data showing pinealon increases melatonin production in cultured pinealocytes. - Animal studies demonstrating improved circadian rhythm markers and sleep quality with pinealon administration. - Theoretical framework of short peptide bioregulation is supported by 30+ years of research at the St. Petersburg Institute. ### Tier 3 (Emerging/Anecdotal) - Clinical observations from European practitioners report improved sleep quality, cognitive function, and subjective well-being in elderly patients. - Practitioner consensus supports use in aging patients with declining sleep quality. - Some practitioners report improved hormonal profiles (cortisol rhythm, GH pulsatility) after sustained pinealon use. ### Key Research Gaps - No Western-standard RCTs or placebo-controlled trials - No pharmacokinetic studies validating oral bioavailability of the tripeptide - Long-term outcomes data is limited to clinical observation - No head-to-head comparison with exogenous melatonin supplementation